Profile data is unavailable for this security.
About the company
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company combines a deep understanding of neuroscience, immunology, disease-related biology, advanced chemistry, and expertise in global clinical trials to advance novel therapies for patients. The Company is engaged in delivering new drug approvals for products for diseases such as migraine and schizophrenia, and its research programs, built on a deep understanding of disease-related biology and neuropharmacology, are advancing novel therapies with indications in spinocerebellar ataxia (SCA), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), epilepsy, depression, obsessive-compulsive disorder (OCD) and neuropathic pain. Its Neuroinnovation portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7 ion channels (Kv7), glutamate receptors, myeloperoxidase (MPO), myostatin, and transient receptor potential (TRP) channels.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated--
- Employees--
- LocationBiohaven Ltd215 Church StreetNEW HAVEN 06510United StatesUSA
- Phone+1 (203) 404-0410
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vericel Corp | 159.26m | -18.10m | 1.01bn | 281.00 | -- | 5.70 | -- | 6.37 | -0.3837 | -0.3837 | 3.39 | 3.77 | 0.6746 | 3.60 | 5.04 | 566,768.70 | -7.67 | -5.85 | -8.49 | -6.74 | 66.29 | 65.61 | -11.36 | -7.18 | 5.54 | -- | 0.0002 | -- | 25.77 | 23.49 | -360.86 | -- | 41.10 | -- |
| Kura Oncology Inc | 0.00 | -135.47m | 1.01bn | 127.00 | -- | 2.37 | -- | -- | -2.03 | -2.03 | 0.00 | 6.27 | 0.00 | -- | -- | 0.00 | -26.85 | -25.80 | -28.15 | -27.27 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -45.57 | -- | -- | -- |
| USANA Health Sciences, Inc. | 1.04bn | 76.88m | 1.02bn | 1.98k | 13.37 | 2.47 | 11.26 | 0.9792 | 3.96 | 3.96 | 53.47 | 21.41 | 1.83 | 2.44 | -- | 524,742.20 | 13.55 | 20.34 | 18.06 | 27.86 | 80.73 | 82.30 | 7.41 | 9.98 | 2.18 | -- | 0.00 | 0.00 | 4.57 | 3.35 | -6.54 | 3.09 | -17.15 | -- |
| Lyell Immunopharma Inc | 39.12m | -258.43m | 1.04bn | 219.00 | -- | 1.26 | -- | 26.51 | -1.04 | -1.04 | 0.158 | 3.29 | 0.036 | -- | -- | 178,625.60 | -23.76 | -- | -25.03 | -- | -- | -- | -660.62 | -- | -- | -- | 0.00 | -- | 37.31 | -- | -22.37 | -- | -- | -- |
| Morphic Holding Inc | 74.23m | -56.07m | 1.06bn | 101.00 | -- | 2.90 | -- | 14.29 | -1.53 | -1.53 | 1.95 | 9.47 | 0.1794 | -- | 45.26 | 734,940.60 | -13.55 | -- | -14.61 | -- | -- | -- | -75.53 | -- | -- | -- | 0.00 | -- | -55.96 | -- | -112.32 | -- | -- | -- |
| Deciphera Pharmaceuticals Inc | 121.89m | -221.39m | 1.08bn | 280.00 | -- | 2.87 | -- | 8.83 | -3.46 | -3.46 | 1.82 | 5.54 | 0.2541 | 0.4581 | 5.90 | 435,321.40 | -46.15 | -44.91 | -54.79 | -50.31 | 95.04 | -- | -181.63 | -556.77 | 5.32 | -- | 0.00 | -- | 128.45 | -- | -12.56 | -- | 92.99 | -- |
| Biohaven Ltd | -100.00bn | -100.00bn | 1.08bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -80.16 | -- | -- | -- |
| Arcutis Biotherapeutics Inc | 725.00k | -310.77m | 1.09bn | 147.00 | -- | 4.04 | -- | 1,510.17 | -5.89 | -5.89 | 0.0139 | 4.45 | 0.0016 | -- | 0.5192 | 4,931.97 | -69.37 | -- | -74.01 | -- | 62.90 | -- | -42,864.14 | -- | 13.27 | -34.85 | 0.4208 | -- | -- | -- | -52.09 | -- | -- | -- |
| Kiniksa Pharmaceuticals Ltd | 177.04m | 142.57m | 1.10bn | 215.00 | 7.89 | 2.85 | 7.56 | 6.19 | 2.00 | 2.00 | 2.55 | 5.52 | 0.4967 | 1.98 | 24.62 | 823,446.50 | 40.00 | -58.06 | 45.85 | -66.59 | 88.67 | -- | 80.53 | -1,684.32 | 4.02 | -- | 0.00 | -- | -- | -- | 2.14 | -- | 484.21 | -- |
| Taro Pharmaceutical Industries Ltd. | 569.41m | 64.98m | 1.10bn | 1.46k | 17.00 | 0.6474 | 11.99 | 1.94 | 1.73 | 1.73 | 15.15 | 45.40 | 0.2574 | 1.44 | 2.56 | 391,347.80 | 2.94 | 3.42 | 3.78 | 3.99 | 49.52 | 61.51 | 11.41 | 12.78 | 3.04 | -- | 0.00 | 0.00 | 2.25 | -8.59 | 115.07 | -33.75 | 25.45 | -- |
| Opko Health Inc. | 1.22bn | -316.95m | 1.14bn | 5.77k | -- | 0.6972 | -- | 0.9309 | -0.4545 | -0.4545 | 1.76 | 2.11 | 0.5257 | 9.54 | 6.45 | 211,580.90 | -13.62 | -5.96 | -15.45 | -6.80 | 27.92 | 35.98 | -25.91 | -12.19 | 1.28 | -22.09 | 0.1338 | -- | 23.64 | 9.69 | -198.55 | -- | 6.43 | -- |
| ImmunoGen, Inc. | 95.61m | -201.09m | 1.14bn | 106.00 | -- | 6.39 | -- | 11.89 | -0.8151 | -0.8151 | 0.3898 | 0.8064 | 0.2917 | -- | 23.42 | 901,952.80 | -61.35 | -35.82 | -91.37 | -48.56 | -- | -- | -210.33 | -121.91 | -- | -62.27 | 0.00 | -- | -47.20 | -- | -213.94 | -- | -- | -- |
| Madrigal Pharmaceuticals Inc | 0.00 | -273.99m | 1.15bn | 71.00 | -- | 107.64 | -- | -- | -16.02 | -16.02 | 0.00 | 0.6239 | 0.00 | -- | -- | 0.00 | -118.27 | -37.85 | -185.70 | -41.31 | -- | -- | -- | -- | -- | -243.42 | 0.8211 | -- | -- | -- | -19.58 | -- | 132.44 | -- |
| CinCor Pharma Inc | 0.00 | -88.09m | 1.16bn | 19.00 | -- | 2.24 | -- | -- | -2.38 | -2.38 | 0.00 | 11.86 | 0.00 | -- | -- | 0.00 | -26.05 | -- | -26.91 | -- | -- | -- | -- | -- | -- | -14.85 | 0.00 | -- | -- | -- | -125.89 | -- | -- | -- |
| Adaptive Biotechnologies Corp | 168.04m | -221.50m | 1.16bn | 858.00 | -- | 2.38 | -- | 6.91 | -1.56 | -1.56 | 1.18 | 3.41 | 0.1791 | 3.13 | 7.70 | 195,850.80 | -23.61 | -- | -26.85 | -- | 66.87 | -- | -131.85 | -- | 5.26 | -- | 0.00 | -- | 56.88 | -- | -41.75 | -- | -- | -- |
Data as of Nov 25 2022. Currency figures normalised to Biohaven Ltd's reporting currency: US Dollar USD
14.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Suvretta Capital Management LLCas of 21 Oct 2022 | 3.84m | 5.64% |
| Armistice Capital LLCas of 30 Sep 2022 | 1.43m | 2.10% |
| Marshall Wace LLPas of 30 Sep 2022 | 1.29m | 1.89% |
| Millennium Management LLCas of 30 Sep 2022 | 1.01m | 1.49% |
| Janus Henderson Investors US LLCas of 30 Sep 2022 | 500.80k | 0.74% |
| Eventide Asset Management LLCas of 30 Sep 2022 | 495.43k | 0.73% |
| SSgA Funds Management, Inc.as of 30 Sep 2022 | 469.54k | 0.69% |
| Monashee Investment Management LLCas of 30 Sep 2022 | 400.00k | 0.59% |
| Point72 Asset Management LPas of 30 Sep 2022 | 379.90k | 0.56% |
| P. Schoenfeld Asset Management LPas of 30 Sep 2022 | 328.00k | 0.48% |
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
